TransMedics Group (TMDX) Competitors

TransMedics Group (NASDAQ:TMDX) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Which has preferable valuation and earnings, TMDX or ZBH?

Zimmer Biomet has higher revenue and earnings than TransMedics Group. Zimmer Biomet is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$441.54M	9.78	$35.46M	$1.36	93.89
Zimmer Biomet	$7.68B	2.41	$903.70M	$4.52	20.69

Is TMDX or ZBH more profitable?

Zimmer Biomet has a net margin of 11.86% compared to TransMedics Group's net margin of 10.03%. TransMedics Group's return on equity of 21.88% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	10.03%	21.88%	6.15%
Zimmer Biomet	11.86%	12.73%	7.34%

Does the media favor TMDX or ZBH?

In the previous week, Zimmer Biomet had 14 more articles in the media than TransMedics Group. MarketBeat recorded 22 mentions for Zimmer Biomet and 8 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.34 beat Zimmer Biomet's score of 0.69 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	12 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of TMDX or ZBH?

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by insiders. Comparatively, 1.4% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, TMDX or ZBH?

TransMedics Group has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Do analysts rate TMDX or ZBH?

TransMedics Group presently has a consensus target price of $127.33, suggesting a potential downside of 0.28%. Zimmer Biomet has a consensus target price of $111.33, suggesting a potential upside of 19.07%. Given Zimmer Biomet's higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80
Zimmer Biomet	2 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.30

Summary

TransMedics Group beats Zimmer Biomet on 9 of the 17 factors compared between the two stocks.